NCT06935357: An ongoing trial by Biogen
This trial is ongoing. It must report results 2 years, 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06935357 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 8, 2025 |
| Completion date | May 31, 2027 |
| Required reporting date | May 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |